ALSO NOTED: Study finds for-profit bias; TorreyPines gets positive data in Phase I; and much more...

> A new study concludes that clinical trials funded by drug companies are more likely to lead to positive results than trials funded by not-for-profit groups. Report

> TorryPines says its Phase I trial for its therapeutic candidate for acute migraines has produced positive data. Report

> Cambridge, MA-based Vertex has launched a Phase I trial of VX-770 as a therapy for cystic fibrosis. Report

> Amarin has acquired global rights to a novel oral formulation of apomorphine for the treatment of "off" episodes in patients with advanced Parkinson's disease. Release

> Genentech will collaborate with Immunogen to develop a manufacturing process for Herceptin. Release

> Intercept Pharmaceuticals has garnered $41 million in equity financing. The financing was led by Milan-based Genextra. Release

> PrimeGen Biotech has created a wholly owned subsidiary--PrimeCell Therapeutics. Release

And Finally… Indonesia has reported five more deaths from bird flu. Article